Kneeland Youngblood served as a director on Core Scientific's board prior to the Company's emergence from bankruptcy on January 23, 2024. He was a member of the Audit Committee and Compensation Committee during the pre-emergence period and was determined to be independent under applicable standards. The Board determined that Youngblood qualified as an audit committee financial expert within the meaning of SEC rules. The source carries no fuller biography regarding his prior employment, education, or roles outside of Core Scientific.
Biography extracted from Core Scientific PRE 14A filed 2025-03-12 View cached copy (2026-08-31)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Core Scientific | Director | 2022-01 → present (4y 10mo) | 3 |
Show 3 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 932,946 | $0 | 800,076 | $0 | Flat | 7 | $12.36M | $10.60M |
| 2024 | 532,908 | $0 | 800,076 | $0 | Flat | 6 | $7.06M | $10.60M |
| 2022 | 400,038 | $0 | - | $0 | Flat | 1 | $5.30M | $0 |
| 2022-Q2 | 400,038 | $0 | - | $0 | Flat | 1 | $5.30M | $0 |
| 2024-Q1 | 532,908 | $0 | 800,076 | $0 | Flat | 6 | $7.06M | $10.60M |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2024-01-23 | Core Scientific | Sale to issuer (buyback) · Common Stock, par value $0.0001 per share | 400,038 | - | $5.30M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Common Stock, par value $0.00001 per share | 40,004 | - | $530.1K |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Tranche 1 Warrants | 50,654 | - | $671.2K |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Tranche 2 Warrants | 42,212 | - | $559.3K |
| 2024-01-23 | Core Scientific | Sale to issuer (buyback) · Common Stock, par value $0.0001 per share | 400,038 | - | $5.30M |
| 2024-01-23 | Core Scientific | Grant / award / vesting · Common Stock, par value $0.00001 per share | 400,038 | - | $5.30M |
| 2022-06-13 | Core Scientific | Grant / award / vesting | 400,038 | - | $5.30M |